RITAPS: A Pilot Study Of Rituximab For The Anticoagulation-Resistant Manifestations Of Antiphospholipid Syndrome (APS)

Doruk Erkan, MD

Co-Investigators

Michael D. Lockshin, MD

Summary

Persistently antiphospholipid antibody (aPL)-positive patients, age 18 - 75 years of age, with anticoagulation-resistant manifestations of APS and fulfilling protocol defined study inclusion criteria will receive two doses of Rituximab, and will be followed for 6 and 12 months for clinical and safety outcomes, respectively.

Inclusion/Exclusion Criteria

Patients are eligible to take part in this study if their blood test is persistently positive for aPL and they have one or more of the aPL-related clinical problem(s) listed  below:

  • Low Platelet (blood cells involved in the prevention of bleeding) Count
  • Anemia (deficiency of red blood cells)
  • Heart Valve Disease
  • Skin Ulcers
  • Kidney Smal Vessel Blood Clots
  • Memory Problems

Contact Information

Joann Vega
Clinical Research Coordinator
Division of Rheumatology
Hospital for Special Surgery
535 East 70th Street, New York, NY 10021
Tel: 212.774.2795
Fax: 212.774.7298
vegaj@hss.edu